RSV Shot Shortages Prompt CDC Guidelines Update

The Centers for Disease Control and Prevention (CDC) has recommended rationing Sanofi's Beyfortus, a monoclonal antibody product used to protect infants from respiratory syncytial virus (RSV), due to shortages. The CDC advises prioritizing available doses for infants under 6 months and those with underlying health conditions at higher risk of severe illness from RSV. The shortage is attributed to high demand and limited manufacturing capacity. The CDC also recommends alternative options, such as Pfizer's Abrysvo vaccine for pregnant individuals and the use of Synagis for eligible children in the 2023-24 season. RSV is a common cause of hospitalization in infants, and while RSV deaths are not common in the US, pediatric hospitals are overwhelmed with RSV cases each year.